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The World Health Organization (WHO) has established specific 
targets for control, elimination or eradication of some vaccine 
preventable infectious diseases, which were periodically updated. 
In Italy, WHO recommendations have been endorsed and imple-
mented over time, through the national and regional health pre-
vention plans. The aim of the study was to assess the impact of the 
immunization practices against measles, varicella and Neisseria 
meningitidis type C (Men C) in Italy and in Tuscany Region, dur-
ing the last decades, by analyzing national and regional surveil-
lance databases. Benefits of vaccination strategies were discussed 
from different points of view (clinical, epidemiological, economic, 
ethical, social and communicative). The implementation of mea-
sles, varicella and Men C vaccination, caused a considerable 
decrease of incidence rates over the years in Italy and in Tuscany 
too. However, in the last years, notifications of measles and Men 
C cases in subjects not targeted by immunization campaigns, in 
Italy and in Tuscany, are a cause for concern for public health 
and for the achievement of the elimination goals. Achieving and 
maintaining high vaccine coverage guarantees a decrease in the 
incidence of serious diseases and their clinical and economic con-
sequences, but it is necessary to strengthen surveillance system 
of infectious diseases in order to monitor epidemiological trends. 
Moreover, outreach campaigns are necessary to raise awareness 
in the general population and create the culture of prevention with 
the same nationwide health goals for all.
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Introduction
Vaccination is one of the most successful health inter-
ventions ever introduced in the history of medicine and, 
together with the modern hygiene practices and the use 
of antibiotics, has contributed significantly to decrease 
infectious diseases. All over the world, introduction of 
universal vaccination resulted in an overall net reduc-
tion of infectious diseases, the main cause of mortality in 
children in the past and, currently, in developing coun-
tries. Indeed, the World Health Organization (WHO) 
estimates that 1.5 million deaths each year could be 
averted thanks to vaccinations that provide protection 
against infectious diseases. However, in 2013 nearly 22 
million children missed out the opportunity to be ade-
quately protected against vaccine preventable diseases, 
resulting in a significant infant mortality, particularly in 
developing countries. Globally, under-five mortality rate 
has decreased by 53%: it has dropped from 91 deaths per 
1000 live births in 1990 to 43 deaths per 1000 live births 
in 2015 [1, 2]. According to the “Global Vaccine Ac-
tion Plan 2011-2020” published by WHO, vaccines will 
prevent 25 million deaths during the current decade [3]. 
However, transmission of infectious diseases could be 
reduced, only achieving and maintaining high level of 
vaccination coverage (VC). The WHO has set specific 
targets for the control, elimination or eradication of dif-
ferent infectious diseases (i.e. measles and polio), which 
were periodically updated. 
In Italy, these targets have been included in all the 
National Health Plans approved in the last decade. In 
particular, in the National Plan for Vaccine Prevention 
2017-2019, specific goals for immunization against 
Measles, Varicella and Meningococcal C diseases were 
defined [4]:
• achieving and maintaining VC for one dose of MMR 
(measles, mumps, rubella) ≥ 95% within 2 years of 
age and two doses of MMR ≥ 95% in children aged 
5-6 years and adolescents (11-18 years);
• achieving and maintaining VC ≥ 95% for meningo-
coccal C vaccination in newborns and adolescents 
(11-18 years) within 2 years of age;
• achieving and maintaining VC ≥ 95% for one dose of 
varicella vaccination within 2 years of age and two 
doses of varicella vaccination ≥ 95% in children of 
5-6 years of age.
In Tuscany, health authorities adopted specific vaccina-
tion strategies against measles, Neisseria meningitidis 
C (Men C) and varicella, in different times, in order to 
reduce the burden of those diseases at regional level and 
contribute to the achievement of national objectives.
The aim of this study was to assess the impact of the 
regional vaccination program in Italy and in Tuscany 
by analyzing and comparing national and regional inci-
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dence data on measles, Men C and varicella before and 
after the introduction of the specific recommendations 
for immunization up to 2010. Moreover, we added some 
considerations on the current epidemiological data of 
measles and Men C cases observed in the last years at 
the regional and national level. 
Benefits of vaccination practices in the field of public 
health were discussed from different points of view: 
clinical, epidemiological, economic, ethical, social and 
communicative. 
The impact of vaccination programs was assessed by 
analyzing epidemiological surveillance data of these 
three infectious diseases in Italy and in Tuscany. The dis-
cussion is supported by specific searches carried out on 
“PubMed” database. A consultation of national and in-
ternational official websites (WHO, UNICEF, Ministry 
of Health, National Institute of Health - ISS Epicentro) 
was also performed in order to retrieve recommenda-
tions on vaccines and vaccination policy in other Italian 
regions or EU countries. 
Evaluation of the impact of vaccination 
in Tuscany and in Italy:  
the clinical-epidemiological value
Measles
In Italy, the introduction of measles (M) and measles-
mumps-rubella (MMR) vaccination determined a signif-
icant decrease in the number of cases and deaths due to 
MMR over time. Figure 1 shows the trend of measles in-
cidence in Tuscany and Italy from 1986 to 2016 and VC 
for one dose of measles-containing vaccines within two 
years of age. Noteworthy, the increase of immunization 
coverage at 24 months of age, that reached in 2010 the 
value of 91% and 92% in Italy and in Tuscany, respec-
tively, corresponds to a drastic decrease in the number 
of measles cases and of incidence rates too (1.4 and 0.7 
per 100,000 in Italy and Tuscany, respectively in 2010). 
Moreover, in 2010 MMR immunization coverage with 
2 doses reached almost 70% at 6, 12 and 15 years of 
age [5]. According to the ICONA study 2008, vaccina-
tion coverage in Italian adolescents (16 years) was 91% 
for 1 dose of MMR and 75% for 2 doses [6], in line with 
the Tuscan VC data.
The incidence of measles in Italy in 2005 reached a his-
toric low of 0.2 cases per 100,000 inhabitants (108 cas-
es). In the period 2003-2007 there was an improvement 
in immunization coverage for the first dose of MMR 
within 24 months (from 84% in 2003 to 90% in 2007), 
and a special surveillance system for measles and rubel-
la cases was established at regional and national level, in 
order to laboratory confirm suspected cases. Moreover, 
in the same period, the second dose of MMR vaccine at 
5-6 years was definitively introduced. However, in Italy 
outbreaks of measles still occur and serious complica-
tions (such as pneumonia, encephalitis and deaths) are 
reported [7, 8]. From July 2009 to September 2010 the 
incidence of measles was 3.6 cases per 100,000 inhab-
itants, with 2,151 cases in 15 regions (of which 42% 
laboratory-confirmed). The average age of cases was 18 
years and 92% of the cases involved unvaccinated peo-
ple. A large percentage of subjects (36%) required hos-
pitalization [9].
The trends of measles incidence rates in Tuscany reflect 
the national one. The VC for MMR in children aged 24 
months in Tuscany gradually increased since 2000 and 
Fig. 1. Measles incidence (x100,000) in Tuscany and Italy from 1986 to 2016 and VC for one dose of measles-containing vaccines within two 
years of age, starting from 1986 for Italy and 1993 for Tuscany, respectively. [Source of Italian data: Ministry of Health available from: http://
www.salute.gov.it/portale/temi/datidefconsMalattie.jsp; Source of Tuscan data: Tuscany Region health authority]. 
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the 2002-03 epidemic of measles occurred in Italy, had a 
less impact in Tuscany than into the other Italian regions. 
In fact, only 330 and 218 cases were notified in 2002 
and in 2003, respectively [10]. In the following years, a 
marked reduction in incidence was still observed, with 
only 3-55 cases reported in 2007 and 2006, but a peak 
of 600 cases occurred in 2008 (16.3 cases/100,000). The 
age group most affected was that of young adults (75%), 
confirming the achievement of optimal vaccination cov-
erage in younger subjects, target of the vaccination pro-
gram. Moreover, in the last years, a high susceptibility to 
measles in young adults in Tuscany was discovered [5]. 
In 2017, an epidemic of measles occurred in Italy and in 
Tuscany too. At national level 4,885 cases and 4 deaths 
were reported from 1 January 2017, including infants and 
adults (median age: 27 years). It involved especially un-
vaccinated subjects (88%) or subjects vaccinated with a 
single dose (6%), causing a high percentage of complica-
tions (35%) and a large number of hospitalizations (44%). 
Moreover, 315 cases occurred among health care workers 
[8]. From January 1 to April 30, 2018, 18 regions have 
reported to the national integrated measles and rubella 
surveillance system 1,258 cases of measles, including 
4 deaths [11]. These evidences reflect the expected epi-
demiological shift of the mean age of infection towards 
older age groups caused by the missed goals of vaccina-
tion coverage in childhood. Improvement of vaccination 
coverage can be reached through additional vaccination 
strategies in hard-to-reach subjects (adolescents or adults) 
who are not included in the routine vaccination offer [12].
Neisseria meningitidis type C
Although Italy, in the period 1994-2012, faced the low-
est incidence rates for invasive meningococcal diseases 
(IMD) compared to other European countries, 3,929 
cases of IMD have been notified to the surveillance sys-
tem of Invasive Bacterial Diseases (MIB), and 2,280 
cases (58.0%) were typed. Serogroup B has always 
been the most common, accounting for 60.3% (1,375 
cases) of cases typed, followed by serogroup C (33%, 
760 cases) [13]. On the other hand, serogroup C isolates 
progressively increased from 1994 to 2005 at national 
level [14, 15]. Figure 2 shows meningococcal meningi-
tis notifications and incidence in Tuscany and Italy from 
2000 to 2016.
In Tuscany, since 2006 a clear reduction in the number 
of Men C cases was observed, probably related to the 
introduction of conjugate vaccines against Men C in the 
regional immunization program. Since 2003, monova-
lent polysaccharide conjugate vaccination against Men 
C in Tuscany was offered to subjects at risk of all ages 
and it was accessible to all the other people in co-pay-
ment. Tuscany was the first Italian region to include Men 
C vaccination in the universal immunization program. 
Since 2005, three doses of vaccine were offered free of 
charge to children at 3, 5 and 13 months of age and one 
catch-up dose for children up to 6 years of age. Start-
ing from 2008, the vaccination schedule was amended, 
and a single dose at 13 months of age to all infants was 
recommended [16]. In 2010, the goal of the Tuscany Re-
gion was to achieve a vaccination coverage of 80% [17]. 
Immunization coverage at 24 months of age, with mono-
valent vaccine against meningococcal C, progressively 
increased year after year, from 68% in 2006 to 90.5% 
in 2011. In 2006 vaccination coverage by birth cohort 
was 49% for children born in 2001 and 68% for children 
born in 2004, similarly in 2009 vaccination coverage 
was 61% for children born in 2000 and 87% for children 
Fig. 2. Meningococcal meningitis notifications and incidence (x 100,000) in Tuscany and Italy from 2000 to 2016. [Source of Italian data: 
Ministry of Health available from: http://www.salute.gov.it/portale/temi/datidefconsMalattie.jsp. Source of Tuscan data: Tuscany Region 
health authority].
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born in 2006 [14]. All cases of Men C observed from 
2006 to 2011 occurred in unvaccinated subjects  [15]. 
However, in 2015-2016 the incidence of IMD in Tus-
cany increased, and some cases occurred in subjects 
vaccinated 8 years before the symptoms onset [18]. For 
this reason, the Tuscany Region adopted a new vaccina-
tion strategy, to give protection to all adolescents already 
vaccinated and adults. Tuscany Region will monitor the 
epidemiological situation and the impact of this cam-
paign will be visible in the coming years [19].
Varicella
In Italy, according to the National Plan for Vaccine Pre-
vention 2012-2014, the decision to recommend the uni-
versal vaccination varicella (UVV) in children has been 
postponed to 2015, for the 2014 birth cohort, when sur-
veillance data on the impact of vaccination programs, al-
ready active in some Italian Regions, including Tuscany, 
will be available [4].
In Tuscany, UVV with two doses of quadrivalent Mea-
sles-Mumps-Rubella-Varicella (MMRV) vaccine is rec-
ommended for children 13-15 months and 5-6 years old 
since July 2008 [15]. UVV, was also endorsed by the 
2010 and 2014 regional immunization schedules [20-
21]. The introduction of UVV in Tuscany and in other 
seven Italian Regions in two doses for all newborns 
achieved remarkable results up to 2014 [22]. The high 
immunization coverage at 24 months of age (84% with 
one dose in 2012) was rapidly achieved in Tuscany, 
thanks to the drawing effect of the trivalent MMR vac-
cine coverage, close to 90%. Data on VC for varicella in 
2016 was about 30% at the national level, because there 
was not a national recommendation since the launch of 
the new National Prevention Plan (2017-2019). While 
in the regions which have already introduced UVV, VC 
reached values between 65% and 86% [23]. Incidence 
rates of varicella cases decreased in the period 2004-
2016 in Tuscany in all age groups (Fig. 3).
The degree of varicella underreporting in Italy, in indi-
viduals from 6 months to 20 years of age, in 2002 was 
7.7 (95% CI 7.4-7.9). Underreporting was greater in 
older age groups and in southern Italy [24]. In Italian 
Central regions the underreporting rate is lower than 
in the South (about 5.4), this could explain the higher 
incidence values registered in Tuscany compared to the 
national average rate, from 2004 to 2010. National vari-
cella notification data from 2011 to 2016 are not avail-
able in the surveillance system. (Fig. 3). Even at Euro-
pean level, existing surveillance systems are affected by 
underreporting and under-ascertainment [25].
Noteworthy, in Tuscany UVV has had a remarkable im-
pact both in clinical-epidemiological and economic as-
pect. The introduction of universal varicella vaccination 
with MMRV in Tuscany has also resulted in a significant 
reduction of varicella-related hospitalisations, especially 
in subjects under 15 years of age and a total reduction 
of related costs. The UVV in Tuscany led to savings 
amounting to Euro 613,121 (Euro 153,280/year) already 
after four years of UVV implementation [26].
In the years 2009-2011 vaccination has had an overall 
rate of reported adverse reactions of 6/10,000 doses 
administered (45 cases out of 77,938 doses). Only 15 
cases of adverse reactions were classified as serious, but 
without permanent damage [27]. Future UVV adoption 
in all Italian regions should be monitored with attention 
in order to avoid a possible shift of cases to adolescence 
or adulthood.
Figure 3. Varicella incidence in Tuscany from 2004 to 2016 and in Italy in the period 2004-2010. [Source of Italian data: Notification data 
2004-2007: http://www.epicentro.iss.it/problemi/varicella/epid.asp and notification data 2008-2010: http://www.salute.gov.it/portale/
temi/p2_6.jsp?lingua=italiano&id=812&area=Malattie%20infettive&menu=vuoto; Source of Tuscan data: Tuscany Region health authority].
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Evaluation of the impact of vaccination: 
economic, ethical, social and 
communicative aspects 
Immunization programs are different between Italian 
Regions, and sometimes these differences occur even 
into the same regional territories, resulting in a great 
heterogeneity of prevention practices at national level. 
In the most recent years Italian Regions have started to 
move towards a common strategy, but on open debate on 
health prevention policies to be adopted, is still going 
on.
Concerning the previous mentioned example of measles 
in Tuscany, increased vaccination coverage in children 
reduces the risk to contract the disease. In fact, vaccina-
tion coverage at 24 months of age has greatly improved 
in recent years at the national level; although, VC targets 
have not yet reached, differences in VC between Italian 
Regions are reducing. The increasing susceptibility to 
measles in young adults suggests the importance to es-
tablish vaccine strategies focused on this age group [12]. 
Moreover, in 2017 measles cases occurred in health care 
workers in Italy. In this professional group, immuniza-
tion status to measles (and to other infectious diseases, 
such as rubella and varicella or pertussis) should be 
monitored. Not only for their direct protection, but also 
for the protection of the patients they care during their 
work; in particular in case of patients at risk of com-
plications (i.e. pregnant women, newborns or immu-
nocompromised subjects). It is fundamental to assess 
the impact of the immunization programs, through the 
monitoring of the VC trends and incidence rates. How-
ever, further efforts are needed to collect coverage and 
notification data in a standardized way in all regions, in 
order to obtain reliable surveillance figures and to plan 
and evaluate immunization programs.
High level of immunization coverage and disease inci-
dence reduction have also been obtained in Tuscany with 
the extended use of monovalent meningococcal C con-
jugate vaccine (MCV). However, recent cases of menin-
gococcal C meningitis occurred in Tuscany even in vac-
cinated subjects, highlighting the need to re-evaluate the 
current vaccination policies for all adolescent. Regional 
health authorities recommended the administration of a 
second dose of meningococcal C vaccine between 6 and 
9 years, to counter the loss of immunity conferred by 
the first dose of vaccine, administered in the second year 
of life [28, 29], and a third dose of MCV was recom-
mended even in adolescence [19].
Previous results about the UVV in Tuscany shown the 
social importance of vaccination as a preventive method, 
which can advantage not only the individual, but also 
the entire community. For many vaccines is possible to 
obtain a herd protection through the achievement of high 
immunization coverage in the target population to protect 
susceptible or vulnerable people inside the community, 
this represents the additional social value of vaccination 
[30]. Indeed, immunization allows the control and con-
tainment of circulation of microorganisms responsible of 
many infectious diseases. Vaccination has the advantage 
of providing protection to the whole community, result-
ing in a significant impact on the population’s health in 
terms of infectious diseases control and reduction of dis-
ease burden (morbidity, mortality, use of medical care, 
hospitalizations), as well as on the decrease of costs at-
tributed to the infectious diseases themselves [31]. In 
Tuscany the high level of varicella VC (84% in 2012) 
resulted in a significant decline in varicella notifications, 
from 33,114 (2004–2007) to 13,184 cases (2009–2012), 
and also of hospitalisations, from 584 (pre-vaccination 
period) to 325 (vaccination period). The hospitalisation 
rate was 4.1 per 100,000 before the introduction of vac-
cination, which dropped to 2.2 per 100,000 in the vac-
cination period [26]. These results obtained in Tuscany 
with UVV are similar to those achieved in other Italian 
regions. Sicily, which was the first Italian Region to of-
fer free UVV to children at 15 months of life and to all 
susceptible adolescents in the twelfth year of age, since 
January 2003, quickly reached a rate of vaccination 
coverage equal to 65.5% in children (12-23 months) 
and 12.1% in adolescents (11-12 years) after 2 years. 
In the same period, the incidence rate of varicella de-
creased from 95.7 / 1,000 person-years in 2004 to 9.0 / 
1,000 person-years in 2007 in pediatric population (0-
13 years) [32, 33]. Since January 2005, Veneto Region 
has offered free UVV to children at 14 months of age, a 
second dose to 6 years old children and a catch-up pro-
gram for 12-year-old children. Moreover, three years 
after the adoption of the varicella vaccination program 
in Veneto, an increase in vaccination coverage (78.6% 
in the cohort of 2008) and a clear decrease in the inci-
dence of varicella in children (0-14 years) has been ob-
served [34-36]. In the general population, the number of 
varicella cases in 2011 reduced by almost 85% compared 
to 2006 (from 13,700 cases to about 2,090 cases) [37].
Vaccination strategies can be implemented differently in 
each Regions depending on their needs, infrastructure 
and healthcare budget. However, ensuring high coverage 
remains the critical success factor for significant preven-
tion of varicella when introducing varicella vaccination 
in the national immunisation programme [38].
More generally, the reduction over time of the incidence 
of vaccine-preventable diseases thanks to the increase of 
the immunization coverage and the loss of risk percep-
tion related to damages caused by infectious diseases in 
the general population, has fostered a tendency to ques-
tion the real need of vaccines [39]. Moreover, in recent 
years refusal to vaccinations based on ideological and 
cultural convictions has gradually emerged [40], some-
times it is associated with a high (and often unfounded) 
perception of the risk of possible vaccination conse-
quences (side effects, adverse reactions). The doubts and 
beliefs that often lead to the choice to vaccinate or not to 
vaccinate should be discussed with health professionals, 
in order to establish a trusting relationship and provide 
accurate, clear, complete, and up to date information. 
Therefore, counseling is the best strategy to guaran-
tee that adherence or non-adherence to vaccination re-
sult from an aware choice [41]. Evidence suggests that 
personalized and targeted counseling, combined with a 
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good health service delivery, could increase vaccination 
coverage even among adults [42].
The decrease of the burden of disease due to vaccina-
tion strategies corresponded in Tuscany to an overall re-
duction of hospitalizations and consequently a decrease 
in the health costs related to hospitalizations and to the 
management of patients. Different Italian studies report 
that in case of a varicella hospitalization, the average 
cost per patient is around 2,050 euros. Azzari et al. in 
their study shown that the real hospitalization costs due 
to varicella are about 30-40% higher than those calcu-
lated with the Diagnosed Related Group (DRG) [43]. 
Vaccinations have also a significant economic impact 
that is higher than the costs supported by the National 
Health Service related to treatment, and included indi-
rect costs generated for the whole society (loss of work 
days for the assistance to an infectious person). A good 
vaccination strategy could contribute to create a healthy 
population which is able to determine the classic engines 
of economic growth: a better education, a more quali-
fied employment and technological progress, as well as 
international appraisal [44].
According to the latest estimates of the WHO-UNICEF, 
even if immunization coverage for childhood diseases 
is over 94% in the European Region, globally at least 
24 million of children are not protected by vaccinations 
and in each country, there are high risk groups of popu-
lation that continue to be susceptible to some diseases 
despite the obvious advantages of vaccinations. In the 
2008-2009 measles outbreaks occurred in some Euro-
pean countries (Austria, Bosnia-Herzegovina, Bulgaria, 
France, Germany, Italy, Poland and Spain), the major-
ity of cases were reported in people who had not been 
vaccinated for philosophical reasons or who were part 
of migrant groups with limited access to immunization 
services. Inequalities in the access to vaccination ser-
vices are due to the different socio-economic conditions 
between countries or even inside a single country. How-
ever, even in countries with high Gross National Product 
(GNP) and high investment on health services and op-
portunities, there were large outbreaks with a high inci-
dence of vaccine preventable diseases, mostly due to the 
influence in the general population of anti-vaccination 
movements, which often, are the cause of the limited 
vaccination acceptance. For example, in 2009, for the 
first time, 95% of measles reported cases were from peo-
ple residing in EU countries with high socio-economic 
level (65% from Western Europe) [45].
The harmonization process of vaccination practices at 
national level should take into account an equal acces-
sibility to healthcare services, territorial differences, the 
effectiveness of vaccinations strategies, moreover com-
municative solutions to contrast the overcome resistance 
in the population should be proposed and realized. The 
achievement and maintenance of high vaccination cover-
age, including high risk people, can guarantee a decrease 
in the incidence rates of infectious diseases and of their 
complications. For this reason it is important to sensitize 
the entire population implementing extraordinary immu-
nization campaigns; trying to overcome territorial dif-
ferences; strengthening all types of surveillance, making 
communication campaigns both for the population and 
for health professionals, involving health professionals 
in the empowerment process of the general population.
Conclusions
In conclusion, all the evidences reported in this study 
confirm that public health vaccination policies, such as 
the ones adopted in Tuscany for the prevention of mea-
sles, meningococcal C diseases and varicella, have a 
high clinical, epidemiological, economic and ethical im-
pact on the society. Vaccination programs should be con-
stantly monitored and updated to reach high protective 
level of immunity inside the community, with particular 
attention to susceptible subjects or high risk groups.
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